Heart Failure
Conditions
Interventions
Cardiac biomarker stabilization group:None
Cardiac biomarker elevation group:None
Cardiac biomarker reduction group:None
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria for heart failure in the 2022 American College of Cardiology/American Heart Association Guidelines for Heart failure Management with reduced ejection fraction, mildly reduced ejection fraction, or preserved ejection fraction; 2. Age 18-85; 3. The expected survival of the patients was greater than 12 months; 4. Patients with good compliance who volunteered for follow-up
Exclusion criteria
Exclusion criteria: 1. Unable to tolerate imaging evaluation of cardiac structure and function due to severe disease; 2. Have a history of drug abuse; 3. Blood biomarkers and imaging indicators cannot be reviewed regularly at follow-up visits; 4. End-stage renal failure (defined as glomerular filtration rate less than 15ml/min.m2)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular death;All-cause death;Heart failure related rehospitalization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Elevated levels of highly sensitive troponin I;BNP levels increase;Reduced left ventricular ejection fraction levels;Elevated left ventricular end diastolic diameter level; | — |
Countries
China
Contacts
Public ContactYing Liu
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed